FDA Declares Tirzepatide Shortage Resolved, Narrowing Room for Compounded Versions
Thursday, June 11th, 2026 - The U.S. Food and Drug Administration has determined that the national shortage of tirzepatide injection, a dual GIP/GLP-1 receptor agonist sold under the brand names Mounjaro and Zepbound, has been resolved, the agency's Center for Drug Evaluation and Research said. Tirzepatide had been listed in shortage since 2022, driven by surging demand for incretin-based therapies for type 2 diabetes and obesity.
The finding carries immediate regulatory weight. When a drug is in FDA-recognized shortage, compounding pharmacies under sections 503A and 503B of federal law have broader latitude to prepare copies. Once a shortage is resolved, that pathway narrows significantly, and pharmacies that continue compounding may face enforcement action.
Compounding pharmacies face a narrower path
The FDA's drug shortages database and its compounding inspections and recalls page outline the mechanisms the agency uses to monitor pharmacies that operate under 503A (traditional compounding) and 503B (outsourcing facility) provisions. The agency has previously issued warning letters to compounders marketing unapproved versions of GLP-1 and GIP/GLP-1 drugs; the FDA warning letters index tracks those actions.
Industry groups representing compounders have argued that patient access depends on compounded alternatives during supply disruptions. The Alliance for Pharmacy Compounding and the Outsourcing Facilities Association have both published positions on drug shortage-related compounding. With the tirzepatide shortage now cleared, those groups may challenge the FDA's determination or pivot toward compounded versions of other incretin drugs still in constrained supply.
Semaglutide supply picture remains mixed
The FDA did not announce a parallel resolution for semaglutide, the GLP-1 receptor agonist sold as Ozempic and Wegovy by Novo Nordisk. Supply constraints for semaglutide have also fueled a parallel compounding market. Medriva's GLP-1 tracker monitors shortage status and compounding enforcement developments as they update.
Pipeline records keep retatrutide in focus
Beyond current-market drugs, ClinicalTrials.gov records show multiple active or recruiting studies for next-generation peptide agents, including retatrutide, Eli Lilly's triple-agonist targeting GLP-1, GIP, and glucagon receptors, and CagriSema, Novo Nordisk's combination of semaglutide with the amylin analogue cagrilintide. Early-stage candidates such as survodutide also appear in trial registries. These programs remain investigational; no regulatory filings for approval have been announced for retatrutide as of this date. Medriva's retatrutide page tracks trial milestones.
Preprint servers including medRxiv and peer-reviewed literature indexed on PubMed continue to generate new data on incretin outcomes, but preprints have not been peer reviewed and should be interpreted with caution.
Athletes face separate rules
The World Anti-Doping Agency's prohibited list covers peptide hormones, growth factors, and related mimetics. Athletes subject to anti-doping codes should verify current WADA rules directly rather than relying on general summaries; prohibited-status designations can differ from those of regulators overseeing prescription medicines.
